You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信升君實生物(01877.HK)目標價至52元 維持「跑贏大市」評級
阿思達克 06-08 14:23
瑞信發表研究報告,指出君實生物(01877.HK)旗下的重組全人源抗SARS-CoV-2單克隆抗體注射液(項目代號:JS016)成為中國最早進入臨床階段的新冠病毒中和抗體。目前第一期的試驗旨在評估JS016在中國人群中的安全性及耐受性。如果一切順利的話,預期第一期的研究將會在7月份完成。在中國以外地區,預期JS016將於6月份成為美國第二個進入臨床階段的新冠病毒中和抗體,相信會在今年下半年完成關鍵性研究。

該行指,由於疫情仍然持續,並有機會在今年秋冬季迎來第二波爆發,認為JS016的商業機會龐大,有望為君實生物2020至2021年帶來約10至20億元人民幣的收入。根據管理層所述,公司目前的產能足以供應予10萬人。

該行維持公司「跑贏大市」投資評級,目標價由原來的49元上調至52元。2020至2021年的收入預測分別上調2.8%及7.4%,以反映JS016的商業化進程有更佳的能見度,認為JS016的持續發展及對解決新冠病毒的迫切需求,會是今年股份的主要催化劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account